- Home
- LYEL vs GALT Comparison
LYEL vs GALT Comparison
Compare LYEL & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LYEL
- GALT
- Stock Information
- Founded
- LYEL 2018
- GALT 2000
- Country
- LYEL United States
- GALT United States
- Employees
- LYEL N/A
- GALT N/A
- Industry
- LYEL Biotechnology: Pharmaceutical Preparations
- GALT Biotechnology: Pharmaceutical Preparations
- Sector
- LYEL Health Care
- GALT Health Care
- Exchange
- LYEL Nasdaq
- GALT Nasdaq
- Market Cap
- LYEL 253.2M
- GALT 232.3M
- IPO Year
- LYEL 2021
- GALT N/A
- Fundamental
- Price
- LYEL $15.95
- GALT $5.67
- Analyst Decision
- LYEL Hold
- GALT Strong Buy
- Analyst Count
- LYEL 3
- GALT 3
- Target Price
- LYEL $16.67
- GALT $6.00
- AVG Volume (30 Days)
- LYEL 27.0K
- GALT 339.7K
- Earning Date
- LYEL 11-12-2025
- GALT 11-14-2025
- Dividend Yield
- LYEL N/A
- GALT N/A
- EPS Growth
- LYEL N/A
- GALT N/A
- EPS
- LYEL N/A
- GALT N/A
- Revenue
- LYEL $60,000.00
- GALT N/A
- Revenue This Year
- LYEL N/A
- GALT N/A
- Revenue Next Year
- LYEL N/A
- GALT N/A
- P/E Ratio
- LYEL N/A
- GALT N/A
- Revenue Growth
- LYEL 11.11
- GALT N/A
- 52 Week Low
- LYEL $7.65
- GALT $0.73
- 52 Week High
- LYEL $30.00
- GALT $6.55
- Technical
- Relative Strength Index (RSI)
- LYEL 47.03
- GALT 62.88
- Support Level
- LYEL $16.29
- GALT $5.04
- Resistance Level
- LYEL $18.60
- GALT $5.36
- Average True Range (ATR)
- LYEL 1.06
- GALT 0.33
- MACD
- LYEL -0.31
- GALT 0.05
- Stochastic Oscillator
- LYEL 6.36
- GALT 60.81
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.